1984 - 1988  B.S, Jilin University

1988 - 1991  M.S, Jilin University

1994 - 1997  Ph.D, China Institute of Atomic Energy

1998 - 2000  Postdoctoral Fellow, Oak Ridge National Laboratory; Washington University School of Medicine

1991 - 2008  Assistant Professor, Associate Professor, and Professor, China Institute of Atomic Energy

2001 -           Professor, Peking University Health Science Center

2013 -           Professor and Principal Investigator (Guest), Institute of Biophysics, Chinese Academy of Sciences

2011  National Outstanding Youth, NSFC

2008  Berson-Yalow Award, Society of Nuclear Medicine, USA

Chairman, Chinese Society for Molecular Imaging

Editorial Board, Bioconjugate Chemistry, Nuclear Science and Techniques

Associate Editor, Biophysics Reports

Director of International Society of Radiopharmaceutical Sciences

Molecular imaging, a rapid growing research field in the last decade, provides a powerful tool for the noninvasive characterization and quantification of biological processes in living subjects at the cellular and molecular levels. Central to molecular imaging is the development of imaging probes. Our research interests focus on the design and development of a series of novel molecular probes targeted to the key biomarkers during disease progress. By optimizing in preclinical animal models and clinical trials, these novel probes are expected to play pivotal roles in early disease detection and staging, as well as real-time response monitoring towards personalized therapy.

1. Ma X, Yao M, Shi J, Li X, Gao Y, Luo Q, Hou R, Liang X* and Wang F*, High Intensity Focused Ultrasound-Responsive and Ultra-stable Cerasomal Perfluorocarbon Nanodroplets for Alleviating Tumor Multidrug Resistance and Epithelial-Mesenchymal Transition, ACS Nano, 2020, DOI: 10.1021/acsnano.0c07287.

2. Gao H^#, Wu Y^#, Shi J^#, Zhang X, Liu T, Hu B, Jia B, Liu Z, Wan Y, Wang F*. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. J Immunother Cancer 2020;0:e001156.

3. Gao S^#, Jia B^#, Feng G^#, Dong C^#, Du H, Bai L, Zhong Q, Ma Q*, Zeng M*, Wang F*. First-in-human pilot study of an integrin α6-targeted radiotracer for SPECT imaging of breast cancer. Sig Transduct Target Ther. 2020, 5:147.

4. Wu Y^#, Li L^#, Wang Z, Shi J, Hu Z, Gao S, Miao W, Ma Q, Dong C*, Wang F*. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe (99m)Tc-HYNIC-H10F, Eur. J. Nucl. Med. Mol. Imaging, 2020. 47, 2613-2623.

5. Yao M, Ma X, Zhang X, Shi L, Liu T, Liang X, Zhao H, Li X, Li L, Gao H, Jia B*, Wang F*. Lectin-mediated pH-sensitive Doxorubicin Prodrug for Pre-targeted Chemotherapy of Colorectal Cancer with Enhanced Efficacy and Reduced Side Effects. Theranostics. 2019, 9(3):747-760.

6. Ma, X.; Li, X.; Shi, J.; Yao, M.; Zhang, X.; Hou, R.; Shao, N.; Luo, Q.; Gao, Y.; Du, S.; Liang, X.*; Wang, F*. Host-Guest Polypyrrole Nanocomplex for Three-Stimuli-Responsive Drug Delivery and Imaging-Guided Chemo-Photothermal Synergetic Therapy of Refractory Thyroid Cancer. Advanced healthcare materials 2019, 8, e1900661.

7. Gao H, Luo C, Yang G, Du S, Li X, Zhao H, Shi J*, and Wang F*. Improved in Vivo Targeting Capability and Pharmacokinetics of ^99mTc-Labeled isoDGR by Dimerization and Albumin-Binding for Glioma Imaging. Bioconjug Chem. 2019 Jul 17;30(7):2038-2048.

8. Jia B^#, Zhang X^#, Wang B, Chen M, Lv F, Wang S *, and Wang F*. Dual-Modal Probe Based on Polythiophene Derivative for Pre- and Intraoperative Mapping of Lymph Nodes by SPECT/Optical Imaging. ACS Appl Mater Interfaces 2018, 10, 6646-6651.

9. Liang X*, Fang L, Li X, Zhang X, Wang F*. Activatable near infrared dye conjugated hyaluronic acid based nanoparticles as a targeted theranostic agent for enhanced fluorescence/CT/photoacoustic imaging guided photothermal therapy. Biomaterials. 2017, 132:72-84.

10. Li, L.^#; Wu, Y.^#; Wang, Z.; Jia, B.; Hu, Z.; Dong, C.; Wang, F*. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe 99mTc-HYNIC-H6F in Breast Cancer Mouse Models. J Nucl Med. 2017, 58, 821-826.

11. Yu X, Wu Y, Liu H, Gao L, Sun X, Zhang C, Shi J, Zhao H, Jia B, Liu Z, Wang F*. Small-Animal SPECT/CT of the Progression and Recovery of Rat Liver Fibrosis by Using an Integrin alphavbeta3-targeting Radiotracer. Radiology, 2016.5.01, 279(2):502~512.

12. Liu Z*, Liu H, Ma T, Sun X, Shi J, Jia B, Sun Y, Zhan J, Zhang H, Zhu Z, Wang F*. Integrin α_vβ₆-targeted SPECT imaging for pancreatic cancer detection. J Nucl Med. 2014, 55(6):989-994.

13. Liu Z*, Sun X, Liu H, Ma T, Shi J, Jia B, Zhao H, Wang F*. Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models. J Nucl Med. 2014, 55(5):818-23.

14. Shi J, Fan D, Dong C, Liu H, Jia B, Zhao H, Jin X, Liu Z, Li F, Wang F*. Anti-tumor Effect of Integrin Targeted ¹⁷⁷Lu-3PRGD2 and Combined Therapy with Endostar. Theranostics. 2014, 4(3):256-266.

15. Zhu Z, Weibing Miao W, Li Q, Dai H, Ma Q, Wang F, Yang A, Jia B, Jing X, Sha L, Shi J, Liu Z, Zhao Z, Wang F*, Li F*. ^99mTc-3PRGD2 for Integrin Receptor Imaging of Lung Cancer: a Multi-Center Study. J Nucl Med. 2012, 53(5):716-722.

16. Liu Z, Liu Y, Jia B, Zhao H, Jin X, Li F, Chen X, Wang F*. Epidermal Growth Factor Receptor-Targeted Radioimmunotherapy of Human Head and Neck Cancer Xenografts Using ⁹⁰Y-Labeled Fully Human Antibody Panitumumab. Mol Cancer Ther. 2010, 9(8):2297-2308.